Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II Trial of Cabozantinib for the Treatment of Radioiodine (RAI)-Refractory Differentiated Thyroid Carcinoma (DTC) in the First-line Setting

NCT02041260 is registered in ClinicalTrials.gov with Thomas Jefferson University as lead sponsor.

NCT NCT02041260
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02041260 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II Trial of Cabozantinib for the Treatment of Radioiodine (RAI)-Refractory Differentiated Thyroid Carcinoma (DTC) in the First-line Setting
Lead sponsor
Thomas Jefferson University
Phase
Phase 2
Overall status
Unknown status
Start date
January 31, 2014
Completion date
May 31, 2022
Enrollment
43 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

differentiated thyroid cancer (dtc), poorly differentiated thyroid cancer